Atri Cure, Inc. ATRC
We take great care to ensure that the data presented and summarized in this overview for AtriCure, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATRC
View all-
Vanguard Group Inc Valley Forge, PA4.75MShares$110 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.23MShares$98.1 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY3.65MShares$84.7 Million0.04% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT2.68MShares$62.2 Million0.48% of portfolio
-
Wellington Management Group LLP Boston, MA1.64MShares$38 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C31.41MShares$32.8 Million0.05% of portfolio
-
First Light Asset Management, LLC Edina, MN1.38MShares$32.1 Million3.29% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL1.37MShares$31.9 Million0.01% of portfolio
-
State Street Corp Boston, MA1.19MShares$27.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.06MShares$24.6 Million0.0% of portfolio
Latest Institutional Activity in ATRC
Top Purchases
Top Sells
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Insider Transactions at ATRC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 30
2024
|
Salvatore Privitera Chief Technical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.62%
|
$110,000
$22.25 P/Share
|
May 13
2024
|
Sven Wehrwein Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+21.19%
|
-
|
May 13
2024
|
Deborah H Telman Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+31.7%
|
-
|
May 13
2024
|
Regina E Groves Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+20.2%
|
-
|
May 13
2024
|
B Kristine Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+14.92%
|
-
|
May 13
2024
|
Maggie Yuen Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+38.44%
|
-
|
May 13
2024
|
Robert S. White Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+7.45%
|
-
|
May 13
2024
|
Shlomo Nachman Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+37.27%
|
-
|
May 13
2024
|
Karen Prange Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,788
+24.56%
|
-
|
May 01
2024
|
Justin J Noznesky Chief Mktg & Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,500
-2.06%
|
$36,000
$24.09 P/Share
|
Apr 01
2024
|
Justin J Noznesky Chief Mktg & Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,500
-2.02%
|
$45,000
$30.39 P/Share
|
Mar 18
2024
|
Karl S. Dahlquist Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,885
-3.57%
|
$60,320
$32.16 P/Share
|
Mar 14
2024
|
Michael H Carrel President, CEO, & Director |
SELL
Bona fide gift
|
Direct |
2,000
-0.3%
|
-
|
Mar 12
2024
|
Justin J Noznesky Chief Mktg & Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,500
-1.98%
|
$54,000
$36.72 P/Share
|
Mar 05
2024
|
Karl S. Dahlquist Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,231
-13.48%
|
$304,547
$37.36 P/Share
|
Mar 01
2024
|
Vinayak Doraiswamy Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,855
-13.04%
|
$318,780
$36.28 P/Share
|
Mar 01
2024
|
Vinayak Doraiswamy Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,622
+18.42%
|
-
|
Mar 01
2024
|
Douglas J Seith Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,596
-8.68%
|
$525,456
$36.28 P/Share
|
Mar 01
2024
|
Douglas J Seith Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,104
+15.27%
|
-
|
Mar 01
2024
|
Karl S. Dahlquist Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,281
+20.66%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 429K shares |
---|---|
Open market or private purchase | 5K shares |
Exercise of conversion of derivative security | 15K shares |
Payment of exercise price or tax liability | 94.7K shares |
---|---|
Bona fide gift | 13.3K shares |
Open market or private sale | 21.4K shares |